The early decisions in drug development shape the trajectory of your drug’s success. Certara pharmacometrics methods quantify drug-patient interactions, optimize dosing strategies, and reduce risks. With over 120 pharmacometricians and 15+ PK-PD programmers, we deliver unparalleled expertise to support your program.
Pharmacometrics Services for Early Drug Development
Pharmacometrics services for early drug development
Quantitative insights to inform key development decisions
Learn more about pharmacometrics services for early drug development
Start strong: Implement pharmacometrics early on
Fit-for-purpose strategies
Our tailored quantitative analysis approaches are purposefully designed to answer critical development questions.
Informed early decisions
Integrating pharmacometrics, strong science and forward-thinking methodologies in early development optimizes drug efficacy, safety, and success, guiding critical decisions with quantitative insights.
Integrated solutions
Benefit from end-to-end support in optimally implementing model informed drug development strategies through access to Certara’s broader drug development services, including regulatory, CMC, DMPK, Toxicology, and Regulatory Services for impactful decision-making.
Certara: The leader in model-informed drug development (MIDD)
Our offerings
Development of pharmacometrics strategy/project plan
Modeling & simulation analysis plans
Population pharmacokinetic (PopPK) analysis
Biomarker PK-PD analysis
Disease progression modeling
Translational PK-PD analysis (animal to man)
Exposure-response analysis of efficacy or safety
Cardiovascular safety analyses (QTc)
Meet our pharmacometrics experts
1 / 7
Experts
Rik de Greef
Senior Vice President, Global Quantitative Sciences Services, Certara Drug Development Solutions
Rik de Greef is a Senior VicePresident of Global Quantitative Science Services at Certara. Rik was trained as a PK-PD scientist at Leiden University, The Netherlands.
Over the years, Rik has taken on roles with increasing responsibilities within Organon and its successor companies Schering-Plough and Merck/MSD. Most recently, has was s...
Connect
2 / 7
Experts
Stephen Duffull
Senior Scientific Advisor, Quantitative Science Services (New Zealand)
Stephen provides advanced pharmacometrics guidance for complex drug development challenges.
Connect
3 / 7
Experts
Adekemi Taylor, PhD
VP Regional Lead USA, Division 1, Quantitative Science Services
Adekemi specializes in in pharmacometric strategy and analyses (including population PK, PK/PD, efficacy and safety exposure-response, and concentration-QTc modeling) to support regulatory filings, study design, and general drug development.
Connect
4 / 7
Experts
Paul Matthias Diderichsen
Senior Vice President, Quantitative Science Services (Europe/Africa)
Paul excels in pharmacometrics modeling, project leadership, and client relations, focusing on decision support and regulatory filings across various therapeutic areas.
Connect
5 / 7
Experts
Mirjam Trame
VP, Certara Drug Development Solutions, Head of Pharmacometrics USA – Division II
Mirjam, a pharmacometrics consultant, serves as the US Lead for Pharmacometrics, Division II, at Certara. With expertise spanning various modalities, including complex biologics, she specializes in Cell and Gene Therapy. Before joining Certara in 2022, Mirjam amassed over 18 years of experience in clinical pharmacology, pharmacometrics, and s...
Connect
6 / 7
Experts
JF Marier, PhD
Sr. Vice President, Integrated Drug Development
JF has 25 years of experience performing PK, PK/PD and exposure-response analyses to support dosing rationale in various therapeutic areas. Specialties include oncology, rare diseases and pediatric populations. Over the last decade, he has provided pharmacometric analyses and strategic decisions that supported the regulatory approval of mor...
Connect
7 / 7
Experts
Amy Cheung, PhD
Vice President, Certara Drug Development Solutions
Dr. Cheung has over a decade of experience working in the pharmaceutical industry at AstraZeneca, with her role as Senior Pharmacometrician and Project manager of AZ Paediatric working group. She obtained her Ph.D. from the University of Manchester, on the topic of Structural Identifiability Analysis in Pharmacokinetic and Pharmacodynamic Mod...
ConnectRelated resources
View allContact us
Jumpstart your drug development with Certara’s world-class pharmacometric experts. With 120+ professionals spanning 5 continents, we deliver data-driven insights to streamline decision-making, minimize risks, and boost your drug’s success. From strategic planning to advanced model-based simulations, our support spans every stage of development. Partner with Certara to transform complex challenges into confident, science-backed decisions. Book your consultation today and take the first step toward bringing your drug to market.
Optimize your drug development strategy
De-risk your clinical trials
Start strong with pharmacometrics to accelerate development and improve outcomes.
Send an Inquiry
Discover more services
FAQs about pharmacometrics consulting
What is pharmacometrics?
Pharmacometrics uses quantitative methods to analyze drug-patient interactions and optimize development decisions.
How early should pharmacometrics be implemented?
It’s ideal to incorporate pharmacometrics during the early stages of drug development for maximum impact.
What types of analyses does Certara offer?
We provide PopPK, PK-PD analysis, disease progression modeling, and more.
